o. Univ.-Prof. Dr. med. Dr. h. c. mult.

Josef Smolen

Josef Smolen

Full Member of the Division of Mathematics and the Natural Sciences since 2005

  • Universitätsklinik für Innere Medizin III, Medizinische Universität Wien

Contact:

Research Areas:

  • Clinical Medicine
  • Rheumatology
  • Immunology
  • Medical diagnostics
  • Disability studies
  • Outcomes research

Selected Memberships:

  • Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften
  • Royal College of Physicians, London
  • American Association of Immunologists
  • American College of Rheumatology
  • Österreichische Gesellschaft für Allergologie und Immunologie
  • Österreichische Gesellschaft für Rheumatologie

Selected Prizes:

  • Dr. h. c. Leiden University, The Netherlands
  • Dr. h. c. Lund University, Sweden
  • Fellow of the Royal College of Physicians, London
  • Ehrenmitglied der Italienischen Gesellschaft für Rheumatologie
  • Ehrenmitglied der Tschechischen Gesellschaft für Rheumatologie

Selected Publications:

  • Smolen, J. S.; Nash, P.; Durez, P. et al. (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet, Bd. 381 (9870), S. 918-929.
  • Smolen, J. S.; Aletaha, D.; Bijlsma, J. W. et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of Rheumatic Diseases, Bd. 69/4, S. 631-637.
  • Smolen, J. S.; Doyle, M. K. et al. (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet, Bd. 374 (9685), S. 210-221.
  • Smolen, J. S.; Beaulieu, A.; Rubbert-Roth, A. et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet, Bd. 371 (9617), S. 987-997.
  • Smolen, J. S.; Kalden, J. R.; Scott, D. L. et al. (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet, Bd. 353 (9149), S. 259-266.